The content above summarizes the research data of the ATM/CHK2/P53 pathway and ATR/CHK1/WEE1 pathway inhibitors, which are still in the development stage in endometrial cancer, and Table 2 summarizes the research of relevant kinase inhibitors in endometrial cancer, including basic studies and clinical trials. This evidence concerns the gene CHEK2 and endometrial cancer.